Origins of BL genes

Tier 1 BL genes

28 total

Gene Summary First BL study Other entities QC result
ARID1A Tier 1 GE1, FE2, aSHM Love et al 3,krysiakRecurrentSomaticMutations2017b?,rossiCodingGenomeSplenic2012c?,wienandGenomicAnalysesFlowsorted2019b?
BACH2 Tier 1 GE4 Grande et al
BCL7A Tier 1 GE4, FEbalinas-gaviraFrequentMutationsAminoterminal2020b?, aSHM Grande et al 5,krysiakRecurrentSomaticMutations2017b?,reichelFlowSortingExome2015a?
BMP7 Tier 1 GE6 Panea et al
CCND3 Tier 1 GErichterRecurrentMutationID32012a?, FE7, aSHM Richter et al 5,8,9
CHD8 Tier 1 GE4 Grande et al
DDX3X Tier 1 GE7, FE10, CEkizhakeyilDDX3XLossAdverse2021?, aSHM Schmitz et al 11,mottokIntegrativeGenomicAnalysis2019b?
FBXO11 Tier 1 GErichterRecurrentMutationID32012a?, FE12, aSHM Richter et al 13,hubschmannMutationalMechanismsShaping2021b?
FOXO1 Tier 1 GE7, FE14, CE14, aSHM Schmitz et al 5,dunsCharacterizationDLBCLPMBL2021b?
GNA13 Tier 1 GE1, FEmuppidiLossSignalingGa132014b?, aSHM Love et al 5,reichelFlowSortingExome2015a?
GNAI2 Tier 1 GE4, aSHM Grande et al 15
HNRNPU Tier 1 GE6, aSHM Panea et al 11
ID3 Tier 1 GErichterRecurrentMutationID32012a?, FErichterRecurrentMutationID32012a?, aSHM Richter et al 7,spinaGeneticsNodalMarginal2016b?
KMT2D Tier 1 GE4, FE16, CE17, aSHM Grande et al 5,8,18,rossiCodingGenomeSplenic2012c?
MYC Tier 1 GE19, FE20, CE21, aSHM Johnston et al 9,dunsCharacterizationDLBCLPMBL2021b?,pasqualucciHypermutationMultipleProtooncogenes2001a?
P2RY8 Tier 1 GEmuppidiLossSignalingGa132014b?, FEmuppidiLossSignalingGa132014b?, aSHM Muppidi et al 22,lohrDiscoveryPrioritizationSomatic2012a?
PHF6 Tier 1 GE23, aSHM Thomas et al 11
PTEN Tier 1 GE1, aSHM Love et al 11
RFX7 Tier 1 GE4, aSHM Grande et al 24
RHOA Tier 1 GErichterRecurrentMutationID32012a?, FE25, aSHM Richter et al 3
SIN3A Tier 1 GE4, aSHM Grande et al chapuyMolecularSubtypesDiffuse2018b?,rossiCodingGenomeSplenic2012c?
SMARCA4 Tier 1 GErichterRecurrentMutationID32012a?, FE26, aSHM Richter et al 11,krysiakRecurrentSomaticMutations2017b?,nadeuGenomicEpigenomicInsights2020b?
TCF3 Tier 1 GE7, FE7 Schmitz et al
TCL1A Tier 1 GE4, aSHM Grande et al 11
TFAP4 Tier 1 GE4, FEtoncUnexpectedSuppressionTumorigenesis2021? Grande et al
TP53 Tier 1 GE27, FErowhTp53DeletionLineage2011?, aSHM Wilda et al 5,18,lohrDiscoveryPrioritizationSomatic2012a?,rossiCodingGenomeSplenic2012c?,tiacciPervasiveMutationsJAKSTAT2018b?
USP7 Tier 1 GE4, aSHM Grande et al 24
WNK1 Tier 1 GE23, aSHM Thomas et al 9,hubschmannMutationalMechanismsShaping2021b?

Tier 2 BL genes

76 total

Gene Summary First BL study Other entities QC result
ADAMTS5 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
ADNP Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
AGO4 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
ARHGEF1 Tier 2 GEmuppidiLossSignalingGa132014b? Muppidi et al
BCL2 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b?, FE28, aSHM Burkhardt et al 5,29,sarkozyMutationalLandscapeGray2021a?
BCL6 Tier 2 GE1, FE28, aSHM Love et al 5,22 PASS
BTG1 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b?, FEmlynarczykBTG1MutationYields2023b?, aSHM Burkhardt et al 5,22,sarkozyMutationalLandscapeGray2021a?
C16orf48 Tier 2 GE7 Schmitz et al
CARD4 Tier 2 GE1 Love et al PASS
CCNF Tier 2 GEabateDistinctViralMutational2015a?, aSHM Abate et al 3
CD79A Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al rossiCodingGenomeSplenic2012c?
CD83 Tier 2 GE6, aSHM Panea et al 15,dunsCharacterizationDLBCLPMBL2021b?,russler-germainMutationsAssociatedProgression2023b? PASS
CDC73 Tier 2 GE1, aSHM Love et al 11 PASS
CDKN2A Tier 2 GE4, CEjardinDiffuseLargeBcell2010a?, aSHM Grande et al 15,spinaGeneticsNodalMarginal2016b?
CDKN2C Tier 2 GE23 Thomas et al
CHD4 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
CPXM2 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
CREBBP Tier 2 GE1, FEpasqualucciInactivatingMutationsAcetyltransferase2011a?, aSHM Love et al 13,dunsCharacterizationDLBCLPMBL2021b?,pasqualucciInactivatingMutationsAcetyltransferase2011a? PASS
CXCR4 Tier 2 GE6, aSHM Panea et al 30,krysiakRecurrentSomaticMutations2017b? PASS
DHCR7 Tier 2 GE7 Schmitz et al
E2F2 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
EBF1 Tier 2 GE23, aSHM Thomas et al 31,reichelFlowSortingExome2015a?
EDNRB Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
EHD1 Tier 2 GE23 Thomas et al
EIF4A1 Tier 2 GE6 Panea et al
ELP2 Tier 2 GE7 Schmitz et al
EPPK1 Tier 2 GE6 Panea et al
ERAP1 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
EXOSC6 Tier 2 GE7 Schmitz et al
EZH2 Tier 2 GE1, FEyapSomaticMutationsEZH22011b?, aSHM Love et al morinSomaticMutationsAltering2010a?,mottokIntegrativeGenomicAnalysis2019b? PASS
FLYWCH1 Tier 2 GE7 Schmitz et al
GGTLA4 Tier 2 GE1 Love et al PASS
GTSE1 Tier 2 GE7 Schmitz et al
HIST1H1E Tier 2 GE4, aSHM Grande et al krysiakRecurrentSomaticMutations2017b?,lohrDiscoveryPrioritizationSomatic2012a?,reichelFlowSortingExome2015a?
HIST1H3D Tier 2 GE6 Panea et al PASS
HIST1H3I Tier 2 GE6 Panea et al krysiakRecurrentSomaticMutations2017b? PASS
HIST1H4J Tier 2 GE6 Panea et al mottokIntegrativeGenomicAnalysis2019b? PASS
HLA-DQB1 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
IGLL5 Tier 2 GE6, aSHM Panea et al 8,chapuyMolecularSubtypesDiffuse2018b?,russler-germainMutationsAssociatedProgression2023b? PASS
IKZF3 Tier 2 GE6, aSHM Panea et al 5 PASS
IRF8 Tier 2 GE6, FE32, aSHM Panea et al 5,mottokIntegrativeGenomicAnalysis2019b? PASS
KANK2 Tier 2 GE7 Schmitz et al
KLHL26 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
KMT2C Tier 2 GE33, aSHM Zhou et al 3,34,sarkozyMutationalLandscapeGray2021a?
MCL1 Tier 2 GE6, aSHM Panea et al 11,dunsCharacterizationDLBCLPMBL2021b? PASS
MIR142 Tier 2 GE4, aSHM Grande et al kwanhianMicroRNA142Mutated202012b?
MKI67 Tier 2 GE7 Schmitz et al russler-germainMutationsAssociatedProgression2023b?
MYO18A Tier 2 GE7 Schmitz et al
NBEAL1 Tier 2 GE1 Love et al PASS
NCOR2 Tier 2 GE7, aSHM Schmitz et al sarkozyMutationalLandscapeGray2021a?,spinaGeneticsNodalMarginal2016b?
NOA1 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
P2RY2 Tier 2 GE1 Love et al PASS
PCBP1 Tier 2 GE7, aSHM Schmitz et al
PDCD11 Tier 2 GE7 Schmitz et al
PIM1 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b?, CE35, aSHM Burkhardt et al 22,dunsCharacterizationDLBCLPMBL2021b?,pasqualucciHypermutationMultipleProtooncogenes2001a?
PLCG2 Tier 2 GE6, aSHM Panea et al fanComprehensiveCharacterizationDriver2020b? PASS
PPP6R2 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
PREX1 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
RANBP6 Tier 2 GE1 Love et al PASS
REV3L Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
RNF144B Tier 2 GE6 Panea et al PASS
RPL10 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
S1PR2 Tier 2 GEmuppidiLossSignalingGa132014b?, FE36, aSHM Muppidi et al 5,22
SAL3 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
TET2 Tier 2 GE23, aSHM Thomas et al albuquerqueEnhancingKnowledgeDiscovery2017a?
TOP2A Tier 2 GE7 Schmitz et al
TTN Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
VWA7 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
WDR90 Tier 2 GE7 Schmitz et al
WHAMM Tier 2 GE7 Schmitz et al
WNK2 Tier 2 GE6 Panea et al PASS
YY1AP1 Tier 2 GE7 Schmitz et al
ZAN Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al
ZBTB7A Tier 2 GEburkhardtClinicalRelevanceMolecular2022b?, aSHM Burkhardt et al 11
ZFP36L1 Tier 2 GE6, aSHM Panea et al 5,reichelFlowSortingExome2015a? PASS
ZNF85 Tier 2 GEburkhardtClinicalRelevanceMolecular2022b? Burkhardt et al

Tier 3 BL genes

70 total

Gene Summary First BL study Other entities QC result
ACAD9 Tier 3 GE1 Love et al FAIL
ACE Tier 3 GE1, aSHM Love et al 3 FAIL
ALPK2 Tier 3 GE6 Panea et al FAIL
ATP2C2 Tier 3 GE1 Love et al FAIL
BRAF Tier 3 GE1, aSHM Love et al tiacciBRAFMutationsHairycell2011a? FAIL
BRD4 Tier 3 GE1, aSHM Love et al 3 FAIL
BTG2 Tier 3 GE1, CE37, aSHM Love et al 5,22 FAIL
C6orf27 Tier 3 GE1 Love et al FAIL
CAD Tier 3 GE1, aSHM Love et al 3 FAIL
CCT6B Tier 3 GE1 Love et al FAIL
CD79B Tier 3 GE6, FE38, aSHM Panea et al 5,22 FAIL
CDH17 Tier 3 GE1 Love et al FAIL
COL4A2 Tier 3 GE1 Love et al FAIL
CTCF Tier 3 GE6 Panea et al FAIL
CYB5D1 Tier 3 GE1 Love et al FAIL
CYP4F22 Tier 3 GE1 Love et al FAIL
DLGAP1 Tier 3 GE1, aSHM Love et al 3 FAIL
DNMT1 Tier 3 GE6 Panea et al FAIL
DTX1 Tier 3 GE1, FE39, CEmerirantaDeltex1MutationsPredict2017b?, aSHM Love et al 3,40,rossiCodingGenomeSplenic2012c? FAIL
EIF2C4 Tier 3 GE1 Love et al FAIL
EML2 Tier 3 GE1 Love et al FAIL
ENTPD3 Tier 3 GE1 Love et al FAIL
EPHB2 Tier 3 GE1 Love et al FAIL
ETS1 Tier 3 GE6, aSHM Panea et al 5 FAIL
FAM129B Tier 3 GE1 Love et al FAIL
FGFR3 Tier 3 GE1 Love et al FAIL
FTCD Tier 3 GE1 Love et al FAIL
FZD3 Tier 3 GE6 Panea et al FAIL
GRIK5 Tier 3 GE1 Love et al FAIL
HIST1H1C Tier 3 GE6, aSHM Panea et al 5 FAIL
HIST1H2AG Tier 3 GE6, aSHM Panea et al 15,krysiakRecurrentSomaticMutations2017b?,rossiCodingGenomeSplenic2012c? FAIL
HIST1H2AM Tier 3 GE6, aSHM Panea et al chapuyMolecularSubtypesDiffuse2018b?,krysiakRecurrentSomaticMutations2017b? FAIL
HIST1H2BK Tier 3 GE6, aSHM Panea et al 3,rossiCodingGenomeSplenic2012c? FAIL
HIST1H3H Tier 3 GE6 Panea et al FAIL
HIST1H3J Tier 3 GE6 Panea et al FAIL
ICK Tier 3 GE1 Love et al FAIL
ITPR3 Tier 3 GE1 Love et al tiacciPervasiveMutationsJAKSTAT2018b? FAIL
KCNK10 Tier 3 GE6 Panea et al FAIL
KIFC3 Tier 3 GE1 Love et al FAIL
MAP3K6 Tier 3 GE1 Love et al FAIL
MME Tier 3 GE6 Panea et al FAIL
MTOR Tier 3 GE6, aSHM Panea et al 3 FAIL
MYH10 Tier 3 GE1 Love et al FAIL
NOTCH1 Tier 3 GE1, CE41, aSHM Love et al 18,42,rossiCodingGenomeSplenic2012c? FAIL
NRXN2 Tier 3 GE1, aSHM Love et al 3 FAIL
PABPC4L Tier 3 GE6 Panea et al FAIL
PC Tier 3 GE1 Love et al FAIL
PCDHA11 Tier 3 GE6 Panea et al FAIL
PDZRN3 Tier 3 GE6, aSHM Panea et al 3 FAIL
PIK3R1 Tier 3 GE6, aSHM Panea et al 3 FAIL
POLRMT Tier 3 GE1 Love et al FAIL
POR Tier 3 GE1 Love et al FAIL
PRSS22 Tier 3 GE1 Love et al FAIL
PTPRN Tier 3 GE1 Love et al FAIL
PXDNL Tier 3 GE6 Panea et al FAIL
RBP3 Tier 3 GE1 Love et al FAIL
RET Tier 3 GE1, aSHM Love et al fanComprehensiveCharacterizationDriver2020b? FAIL
SALL3 Tier 3 GE1 Love et al 34 FAIL
SAPS2 Tier 3 GE1 Love et al FAIL
SBF1 Tier 3 GE1 Love et al FAIL
SF3B1 Tier 3 GE1, aSHM Love et al 11 FAIL
SHANK1 Tier 3 GE1 Love et al FAIL
SLC29A2 Tier 3 GE1 Love et al FAIL
SNTB2 Tier 3 GE6 Panea et al FAIL
SYNGAP1 Tier 3 GE1 Love et al FAIL
TBC1D9B Tier 3 GE1 Love et al FAIL
TIGD6 Tier 3 GE1 Love et al FAIL
TPST2 Tier 3 GE1 Love et al FAIL
WDR7 Tier 3 GE6 Panea et al FAIL
ZNF229 Tier 3 GE1 Love et al FAIL

References

1.
Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WWL, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012 Dec;44(12):1321–1325. PMCID: PMC3674561
2.
Barisic D, Chin CR, Meydan C, Teater M, Tsialta I, Mlynarczyk C, Chadburn A, Wang X, Sarkozy M, Xia M, Carson SE, Raggiri S, Debek S, Pelzer B, Durmaz C, Deng Q, Lakra P, Rivas M, Steidl C, Scott DW, Weng AP, Mason CE, Green MR, Melnick A. ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer Cell. 2024 Apr 8;42(4):583–604.e11.
3.
Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, Naresh K, Evens A, Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A, Walsh K, Jima D, Smith LL, Johnson AJ, Byrd JC, Luftig MA, Ni T, Zhu J, Chadburn A, Levy S, Dunson D, Dave SS. Genetic heterogeneity of diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:1398–1403. PMCID: PMC3557051
4.
Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, Allen H, Ayers LW, Bethony JM, Bhatia K, Bowen J, Casper C, Choi JK, Culibrk L, Davidsen TM, Dyer MA, Gastier-Foster JM, Gesuwan P, Greiner TC, Gross TG, Hanf B, Harris NL, He Y, Irvin JD, Jaffe ES, Jones SJM, Kerchan P, Knoetze N, Leal FE, Lichtenberg TM, Ma Y, Martin JP, Martin MR, Mbulaiteye SM, Mullighan CG, Mungall AJ, Namirembe C, Novik K, Noy A, Ogwang MD, Omoding A, Orem J, Reynolds SJ, Rushton CK, Sandlund JT, Schmitz R, Taylor C, Wilson WH, Wright GW, Zhao EY, Marra MA, Morin RD, Staudt LM. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019;133(12):1313–1324. PMCID: PMC6428665
5.
Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJM, Connors JM, Hirst M, Gascoyne RD, Marra MA. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011 Jul 27;476(7360):298–303. PMCID: PMC3210554
6.
Panea R, Love C, Shingleton JR, Reddy A, Bailey J, Moormann A, Otieno J, Ong’echa J, Oduor C, Schroêder K, Masalu N, Chao N, Agajanian M, Major M, Fedoriw Y, Richards K, Rymkiewicz G, Miles R, Alobeid B, Bhagat G, Flowers C, Ondrejka S, Hsi E, Choi W, Au-Yeung R, Hartmann W, Lenz G, Meyerson H, Lin YY, Zhuang Y, Luftig M, Waldrop A, Dave T, Thakkar D, Sahay H, Li G, Palus B, Seshadri V, Kim S, Gascoyne R, Levy S, Mukhopadhyay M, Dunson D, Dave S. The whole genome landscape of Burkitt lymphoma subtypes. Blood. 2019;
7.
Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012 Oct 4;490(7418):116–120. PMCID: PMC3609867
8.
Desch AK, Hartung K, Botzen A, Brobeil A, Rummel M, Kurch L, Georgi T, Jox T, Bielack S, Burdach S, Classen CF, Claviez A, Debatin KM, Ebinger M, Eggert A, Faber J, Flotho C, Frühwald M, Graf N, Jorch N, Kontny U, Kramm C, Kulozik A, Kühr J, Sykora KW, Metzler M, Müller HL, Nathrath M, Nüßlein T, Paulussen M, Pekrun A, Reinhardt D, Reinhard H, Rössig C, Sauerbrey A, Schlegel PG, Schneider DT, Scheurlen W, Schweigerer L, Simon T, Suttorp M, Vorwerk P, Schmitz R, Kluge R, Mauz-Körholz C, Körholz D, Gattenlöhner S, Bräuninger A. Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia. 2020 Jan;34(1):151–166.
9.
Jallades L, Baseggio L, Sujobert P, Huet S, Chabane K, Callet-Bauchu E, Verney A, Hayette S, Desvignes JP, Salgado D, Levy N, Béroud C, Felman P, Berger F, Magaud JP, Genestier L, Salles G, Traverse-Glehen A. Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma. Haematologica. 2017 Oct;102(10):1758–1766. PMCID: PMC5622860
10.
Gong C, Krupka JA, Gao J, Grigoropoulos NF, Giotopoulos G, Asby R, Screen M, Usheva Z, Cucco F, Barrans S, Painter D, Zaini NBM, Haupl B, Bornelöv S, Ruiz De Los Mozos I, Meng W, Zhou P, Blain AE, Forde S, Matthews J, Khim Tan MG, Burke GAA, Sze SK, Beer P, Burton C, Campbell P, Rand V, Turner SD, Ule J, Roman E, Tooze R, Oellerich T, Huntly BJ, Turner M, Du MQ, Samarajiwa SA, Hodson DJ. Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Molecular Cell. 2021;
11.
Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell. 2017 Oct;171(2):481–494.e15. PMCID: PMC5659841
12.
Schneider C, Kon N, Amadori L, Shen Q, Schwartz FH, Tischler B, Bossennec M, Dominguez-Sola D, Bhagat G, Gu W, Basso K, Dalla-Favera R. FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease. Blood. 2016 Aug 4;128(5):660–666. PMCID: PMC9709922
13.
Parry M, Rose-Zerilli MJJ, Gibson J, Ennis S, Walewska R, Forster J, Parker H, Davis Z, Gardiner A, Collins A, Oscier DG, Strefford JC. Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS One. 2013;8(12):e83244. PMCID: PMC3862727
14.
Trinh DL, Scott DW, Morin RD, Mendez-Lago M, An J, Jones SJM, Mungall AJ, Zhao Y, Schein J, Steidl C, Connors JM, Gascoyne RD, Marra MA. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013;121(18):3666–3674. PMCID: PMC3643765
15.
Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD, Scott DW, Ding J, Roth A, Chiu R, Corbett RD, Chan FC, Mendez-Lago M, Trinh DL, Bolger-Munro M, Taylor G, Hadj Khodabakhshi A, Ben-Neriah S, Pon J, Meissner B, Woolcock B, Farnoud N, Rogic S, Lim EL, Johnson NA, Shah S, Jones S, Steidl C, Holt R, Birol I, Moore R, Connors JM, Gascoyne RD, Marra MA. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013 Aug 15;122(7):1256–1265. PMCID: PMC3744992
16.
Li J, Chin CR, Ying HY, Meydan C, Teater MR, Xia M, Farinha P, Takata K, Chu CS, Jiang Y, Eagles J, Passerini V, Tang Z, Rivas MA, Weigert O, Pugh TJ, Chadburn A, Steidl C, Scott DW, Roeder RG, Mason CE, Zappasodi R, Béguelin W, Melnick AM. Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nat Commun. 2024 Apr 3;15(1):2879. PMCID: PMC10991284
17.
Rushton CK, Arthur SE, Alcaide M, Cheung M, Jiang A, Coyle KM, Cleary KLS, Thomas N, Hilton LK, Michaud N, Daigle S, Davidson J, Bushell K, Yu S, Rys RN, Jain M, Shepherd L, Marra MA, Kuruvilla J, Crump M, Mann K, Assouline S, Connors JM, Steidl C, Cragg MS, Scott DW, Johnson NA, Morin RD. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Adv. 2020 Jul 14;4(13):2886–2898. PMCID: PMC7362366
18.
Beà S, Valdés-Mas R, Navarro A, Salaverria I, Martín-Garcia D, Jares P, Giné E, Pinyol M, Royo C, Nadeu F, Conde L, Juan M, Clot G, Vizán P, Croce LD, Puente DA, López-Guerra M, Moros A, Roue G, Aymerich M, Villamor N, Colomo L, Martínez A, Valera A, Martín-Subero JI, Amador V, Hernández L, Rozman M, Enjuanes A, Forcada P, Muntañola A, Hartmann EM, Calasanz MJ, Rosenwald A, Ott G, Hernández-Rivas JM, Klapper W, Siebert R, Wiestner A, Wilson WH, Colomer D, López-Guillermo A, López-Otín C, Puente XS, Campo E. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. PNAS. 2013;110(45):18250–18255.
19.
Johnston JM, Carroll WL. C-myc hypermutation in Burkitt’s lymphoma. Leuk Lymphoma. 1992 Dec;8(6):431–439.
20.
Giallongo A, Appella E, Ricciardi R, Rovera G, Croce CM. Identification of the c-myc oncogene product in normal and malignant B cells. Science. 1983 Oct 28;222(4622):430–432.
21.
Christie L, Kernohan N, Levison D, Sales M, Cunningham J, Gillespie K, Batstone P, Meiklejohn D, Goodlad J. C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator? Leuk Lymphoma. 2008 Mar;49(3):470–476.
22.
Dreval K, Hilton LK, Cruz M, Shaalan H, Ben-Neriah S, Boyle M, Collinge B, Coyle KM, Duns G, Farinha P, Grande BM, Meissner B, Pararajalingam P, Rushton CK, Slack GW, Wong J, Mungall AJ, Marra MA, Connors JM, Steidl C, Scott DW, Morin RD. Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns. Blood. 2023 Aug 10;142(6):561–573. PMCID: PMC10644066
23.
Thomas N, Dreval K, Gerhard DS, Hilton LK, Abramson JS, Ambinder RF, Barta S, Bartlett NL, Bethony J, Bhatia K, Bowen J, Bryan AC, Cesarman E, Casper C, Chadburn A, Cruz M, Dittmer DP, Dyer MA, Farinha P, Gastier-Foster JM, Gerrie AS, Grande BM, Greiner T, Griner NB, Gross TG, Harris NL, Irvin JD, Jaffe ES, Henry D, Huppi R, Leal FE, Lee MS, Martin JP, Martin MR, Mbulaiteye SM, Mitsuyasu R, Morris V, Mullighan CG, Mungall AJ, Mungall K, Mutyaba I, Nokta M, Namirembe C, Noy A, Ogwang MD, Omoding A, Orem J, Ott G, Petrello H, Pittaluga S, Phelan JD, Ramos JC, Ratner L, Reynolds SJ, Rubinstein PG, Sissolak G, Slack G, Soudi S, Swerdlow SH, Traverse-Glehen A, Wilson WH, Wong J, Yarchoan R, ZenKlusen JC, Marra MA, Staudt LM, Scott DW, Morin RD. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma. Blood. 2023 Feb 23;141(8):904–916. PMCID: PMC10023728
24.
Arthur SE, Jiang A, Grande BM, Alcaide M, Cojocaru R, Rushton CK, Mottok A, Hilton LK, Lat PK, Zhao EY, Culibrk L, Ennishi D, Jessa S, Chong L, Thomas N, Pararajalingam P, Meissner B, Boyle M, Davidson J, Bushell KR, Lai D, Farinha P, Slack GW, Morin GB, Shah S, Sen D, Jones SJM, Mungall AJ, Gascoyne RD, Audas TE, Unrau P, Marra MA, Connors JM, Steidl C, Scott DW, Morin RD. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nat Commun. 2018 Oct 1;9(1):4001. PMCID: PMC6167379
25.
O’Hayre M, Inoue A, Kufareva I, Wang Z, Mikelis CM, Drummond RA, Avino S, Finkel K, Kalim KW, DiPasquale G, Guo F, Aoki J, Zheng Y, Lionakis MS, Molinolo AA, Gutkind JS. Inactivating mutations in GNA13 and RHOA in Burkitt’s lymphoma and diffuse large B-cell lymphoma: A tumor suppressor function for the Gα13/RhoA axis in B cells. Oncogene. 2016 Jul 21;35(29):3771–3780. PMCID: PMC4885800
26.
Deng Q, Lakra P, Gou P, Yang H, Meydan C, Teater M, Chin C, Zhang W, Dinh T, Hussein U, Li X, Rojas E, Liu W, Reville PK, Kizhakeyil A, Barisic D, Parsons S, Wilson A, Henderson J, Scull B, Gurumurthy C, Vega F, Chadburn A, Cuglievan B, El-Mallawany NK, Allen C, Mason C, Melnick A, Green MR. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer Cell. 2024 Apr 8;42(4):605–622.e11. PMCID: PMC11003852
27.
Wilda M, Bruch J, Harder L, Rawer D, Reiter A, Borkhardt A, Woessmann W. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt’s lymphoma in children. Leukemia. 2004 Mar;18(3):584–588.
28.
Bal E, Kumar R, Hadigol M, Holmes AB, Hilton LK, Loh JW, Dreval K, Wong JCH, Vlasevska S, Corinaldesi C, Soni RK, Basso K, Morin RD, Khiabanian H, Pasqualucci L, Dalla-Favera R. Super-enhancer hypermutation alters oncogene expression in B cell lymphoma. Nature. 2022 Jul;607(7920):808–815. PMCID: PMC9583699
29.
Tanaka S, Louie DC, Kant JA, Reed JC. Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin’s lymphomas. Blood. 1992 Jan 1;79(1):229–237.
30.
Khodabakhshi AH, Morin RD, Fejes AP, Mungall AJ, Mungall KL, Bolger-Munro M, Johnson NA, Connors JM, Gascoyne RD, Marra MA, Birol I, Jones SJM. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget. 2012;3(11):1308–1319. PMCID: PMC3717795
31.
Bohle V, Döring C, Hansmann M-L, Küppers R. Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma. Leukemia. 2013 Mar;27(3):671–679.
32.
Qiu Z, Khalife J, Ethiraj P, Jaafar C, Lin AP, Holder KN, Ritter JP, Chiou L, Huelgas-Morales G, Aslam S, Zhang Z, Liu Z, Arya S, Gupta YK, Dahia PLM, Aguiar RCT. IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHCII complexes. Sci Adv. 2024 Jul 12;10(28):eadk2091. PMCID: PMC11244530
33.
Zhou P, Blain AE, Newman AM, Zaka M, Chagaluka G, Adlar FR, Offor UT, Broadbent C, Chaytor L, Whitehead A, Hall A, O’Connor H, Van Noorden S, Lampert I, Bailey S, Molyneux E, Bacon CM, Bomken S, Rand V. Sporadic and endemic Burkitt lymphoma have frequent FOXO1 mutations but distinct hotspots in the AKT recognition motif. Blood Adv. 2019 Jul 23;3(14):2118–2127. PMCID: PMC6650741
34.
Zhang J, Jima D, Moffitt AB, Liu Q, Czader M, Hsi ED, Fedoriw Y, Dunphy CH, Richards KL, Gill JI, Sun Z, Love C, Scotland P, Lock E, Levy S, Hsu DS, Dunson D, Dave SS. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood. 2014 May 8;123(19):2988–2996.
35.
Guo B, Huang Y, Duan Y, Liao C, Cen H. SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups. Cancer Med. 2022 Mar;11(5):1281–1291. PMCID: PMC8894717
36.
Flori M, Schmid CA, Sumrall ET, Tzankov A, Law CW, Robinson MD, Müller A. The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling. Blood. 2016 Mar 17;127(11):1438–1448.
37.
Guo D, Hong L, Ji H, Jiang Y, Lu L, Wang X, Huang H. The Mutation of BTG2 Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma. J Inflamm Res. 2022;15:1757–1769. PMCID: PMC8923029
38.
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010 Jan;463(7277):88–92. PMCID: PMC2845535
39.
de Miranda NFCC, Georgiou K, Chen L, Wu C, Gao Z, Zaravinos A, Lisboa S, Enblad G, Teixeira MR, Zeng Y, Peng R, Pan-Hammarström Q. Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. Blood. 2014 Oct 16;124(16):2544–2553. PMCID: PMC4199956
40.
Gomez F, Fisk B, McMichael JF, Mosior M, Foltz JA, Skidmore ZL, Duncavage EJ, Miller CA, Abel H, Li YS, Russler-Germain DA, Krysiak K, Watkins MP, Ramirez CA, Schmidt A, Martins Rodrigues F, Trani L, Khanna A, Wagner JA, Fulton RS, Fronick CC, O’Laughlin MD, Schappe T, Cashen AF, Mehta-Shah N, Kahl BS, Walker J, Bartlett NL, Griffith M, Fehniger TA, Griffith OL. Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma. Cancer Res Commun. 2023 Nov 15;3(11):2312–2330. PMCID: PMC10648575
41.
Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B, Gunawardana J, Jenkins C, Cochrane C, Ben-Neriah S, Tan K, Morin RD, Opat S, Sehn LH, Connors JM, Marra MA, Weng AP, Steidl C, Gascoyne RD. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012 Mar 1;119(9):1963–1971.
42.
Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, Chan J, Bhagat G, Chadburn A, Gaidano G, Mullighan CG, Rabadan R, Dalla-Favera R. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011 Jul 31;43(9):830–837. PMCID: PMC3297422